Cooperative p16 and p21 action protects female astrocytes from transformation by Kfoury, Najla et al.




Cooperative p16 and p21 action protects female
astrocytes from transformation
Najla Kfoury
Washington University School of Medicine in St. Louis
Tao Sun
Washington University School of Medicine in St. Louis
Kwanha Yu
Baylor College of Medicine
Nathan Rockwell
Washington University School of Medicine in St. Louis
Kelsey L. Tinkum
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Kfoury, Najla; Sun, Tao; Yu, Kwanha; Rockwell, Nathan; Tinkum, Kelsey L.; Qi, Zongtai; Warrington, Nicole M.; McDonald, Peter;
Roy, Anuradha; Weir, Scott J.; Mohila, Carrie A.; Deneen, Benjamin; and Rubin, Joshua B., ,"Cooperative p16 and p21 action protects
female astrocytes from transformation." Acta Neuropathologica Communications.6,. 12. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6727
Authors
Najla Kfoury, Tao Sun, Kwanha Yu, Nathan Rockwell, Kelsey L. Tinkum, Zongtai Qi, Nicole M. Warrington,
Peter McDonald, Anuradha Roy, Scott J. Weir, Carrie A. Mohila, Benjamin Deneen, and Joshua B. Rubin
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6727
RESEARCH Open Access
Cooperative p16 and p21 action protects
female astrocytes from transformation
Najla Kfoury1†, Tao Sun1†, Kwanha Yu2, Nathan Rockwell1, Kelsey L. Tinkum1, Zongtai Qi3, Nicole M. Warrington1,
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Abstract
Mechanisms underlying sex differences in cancer incidence are not defined but likely involve dimorphism (s) in
tumor suppressor function at the cellular and organismal levels. As an example, sexual dimorphism in retinoblastoma
protein (Rb) activity was shown to block transformation of female, but not male, murine astrocytes in which
neurofibromin and p53 function was abrogated (GBM astrocytes). Correlated sex differences in gene expression
in the murine GBM astrocytes were found to be highly concordant with sex differences in gene expression in
male and female GBM patients, including in the expression of components of the Rb and p53 pathways. To
define the basis of this phenomenon, we examined the functions of the cyclin dependent kinase (CDK) inhibitors,
p16, p21 and p27 in murine GBM astrocytes under conditions that promote Rb-dependent growth arrest. We
found that upon serum deprivation or etoposide-induced DNA damage, female, but not male GBM astrocytes,
respond with increased p16 and p21 activity, and cell cycle arrest. In contrast, male GBM astrocytes continue to
proliferate, accumulate chromosomal aberrations, exhibit enhanced clonogenic cell activity and in vivo tumorigenesis;
all manifestations of broad sex differences in cell cycle regulation and DNA repair. Differences in tumorigenesis
disappeared when female GBM astrocytes are also rendered null for p16 and p21. These data elucidate mechanisms
underlying sex differences in cancer incidence and demonstrate sex-specific effects of cytotoxic and targeted
therapeutics. This has critical implications for lab and clinical research.
Keywords: Sex differences, Glioblastoma, Glioma, Rb, p16, p21, Cyclin dependent kinase inhibitors, DNA damage
response
Introduction
Increasing volumes of data indicate significant sex differ-
ences exist in many human diseases [10, 14, 20, 24, 29,
31]. Sex differences in incidence presumably reflect dif-
ferences in the mechanisms that determine vulnerability
to disease [15, 25, 33, 35, 37]. The most recent
epidemiological data indicate that cancer occurs at sig-
nificantly greater frequency in males compared to fe-
males [27, 28, 44]. With few exceptions, most notably
those cancers that are sex hormone responsive, greater
male prevalence is true regardless of age, cancer type,
race, or region of the world. Defining the molecular,
cellular and organismal bases for sex differences in indi-
vidual diseases and cancers will determine what, if any,
measures need to be taken to tailor precision medicine
approaches in a sex-specific manner in order to optimize
outcome.
Multiple factors can contribute to sex differences in
human health and disease. Significant sex differences in
metabolism, gene expression and growth regulation are
evident from the moment of fertilization and persist
throughout life [36]. From conception on, sex differences
arise through the multiple mechanisms of sexual differ-
entiation. Starting with differences in sex chromosome
complement and sex specific reprogramming of
imprinted loci, and continuing with the organizational
or epigenetic effects of in utero and pubertal sex hor-
mones, and finally maturing with the acute action of
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circulating sex hormones, sex differences are powerfully
ensconced at the cellular and organismal levels.
Glioblastoma, the most common malignant brain
tumor, occurs with a male to female incidence ratio of
1.6:1 in the United States [27]. While multiple mecha-
nisms may contribute to the incidence difference, prior
studies indicate that cell intrinsic sex differences in the
response to tumor suppressor loss within the astrocyte
lineage may be among the reasons [37]. In these stud-
ies, sex differences in regulation of Rb were correlated
with differences in clonogenic cell function, prolifera-
tion and in vivo tumorigenesis. Here, we investigate
how the cyclin dependent kinase (CDK) inhibitors p16,
p21 and p27 contribute to sex differences in Rb regula-
tion, tumorigenesis and response to DNA damage. The
results of these studies provide new evidence of the im-
portance of considering the biology of sex differences
in cancer and more broadly, in any disease with sex dif-
ferences in incidence or outcome. They advance our
understanding of the molecular basis for sex differences
in growth regulation and how these differences might
underlie the sex differences in cancer incidence. Finally,
they suggest that clinical trial design for novel cancer
therapeutics should incorporate the possibility of sex
differences in response.
Results
In published studies, we found that combined loss of
neurofibromin and p53 function was transforming for
male, but not female astrocytes [37]. To be certain that
these sex differences in transformation were not limited
to specific features of our model, we sought to deter-
mine whether we would see similar results in a different
model. We therefore measured in vivo tumorigenesis in
male and female Cas9-expressing CD-1 IGS mice fol-
lowing in utero electroporation of gRNAs targeting the
Nf1 and p53 genes into peri-ventricular neural progeni-
tors. Two pX330 vectors [13] with guide sequence
inserts targeting Nf1 and p53 were injected into the lat-
eral ventricles of embryonic day 15–16 pups (E15–16),
and progenitor cells were targeted via bioelectropora-
tion. This model is referred to as the CRISPR-IUE
Glioma Model [21] (Fig. 1a and Additional file 1: Figure
S1A). All male and female mice receiving the CRISPR
IUEs were euthanized for neurological deficits or exces-
sive weight loss. In all cases, large tumors were
Fig. 1 Deletion of neurofibromin and p53 in vivo results in sexually dimorphic gliomagenesis. a Schematic of bioelectroporation strategy. The
uterus is delivered intact to the external environment (left hand panel). The cerebral ventricles are identified in each pup by trans-illumination
and injected with gRNAs directed against neurofibromin and p53 (middle panel). An electric field is imposed across the head of each pup to drive
the gRNAs into the sub-ventricular region (right hand panel). b Survival was significantly shorter for male mice compared to female mice. While
all mice succumbed to tumors, median survival for male mice (n = 11) was 176 days and for female mice (n = 14), 238 days. p = 0.0031 as determined
by log-rank test of Kaplan-Meier survival curves. c Large invasive tumors formed in all mice. d Tumors were diagnosed as astrocytomas based on their
expression of glial fibrillary acidic protein (GFAP, brown-right). Corresponding H&E (right) and GFAP (left) staining from a CRISPR IUE brain/tumor
section are shown. e Tumors were invasive (asterisk) and had other characteristic glioblastoma features like necrosis (f), asterisk) and abundant mitoses
(g), asterisks) evident on examination of hematoxylin and eosin (H&E) stained sections. Scale bars (e, f) = 100 μM. Scale bar (d, g) = 50 μM
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confirmed by direct inspection and histopathology.
While combined loss of neurofibromin and p53 func-
tion was tumorigenic in 100% of male and female mice,
the process was accelerated in male mice in which
median survival was 176 days compared to 238 days for
female mice (Fig. 1b). The sex differences in survival
were statistically significant with a p-value of 0.0031 as
determined by Log-Rank test. Both male and female
tumors were characteristically large at the time of eu-
thanasia (Fig. 1c) and diagnosed as glioblastoma-like
based on expression of glial fibrillary acidic protein
(Fig. 1d), and standard histological features including
invasion (Fig. 1e), necrosis (Fig. 1f ) and abundant mi-
toses (Fig. 1g). In general, female tumors exhibited
more necrosis than male tumors, while male tumors
exhibited more rosettes, a primitive neuro-ectodermal
(PNET)-like features (Additional file 1: Figure S1B).
Increased necrosis has also been reported to be a more
prominent feature in female patient pathological speci-
mens and magnetic resonance imaging [9, 12].
Together, these data indicate that sex differences in
tumorigenesis after combined loss of neurofibromin
and p53 function are evident in different mouse strains
and regardless of whether the loss is engineered in vitro
or in vivo and independent of the method by which p53
function is abrogated.
To gain further insights into the molecular basis for
these differences in male and female cell behaviors, we
performed transcriptomic analyses using RNA sequen-
cing in astrocytes rendered null for neurofibromin and
p53 function. Briefly, male and female astrocytes were
isolated from the neocortices of postnatal day 1 Nf1fl/fl
GFAP-Cre mice and genotyped for sex using Jarid1c and
Jarid1d PCR. Male and female Nf1−/− astrocytes were
then infected with retrovirus encoding a flag-tagged
dominant-negative form of p53 (DNp53) and EGFP
resulting in male and female astrocytes null for Nf1 and
p53 function [37]. The DNp53 plasmid consists of
amino acids 1–14 of the transactivation domain followed
by amino acids 303–393 thus lacking the DNA binding
domain. These astrocytes serve as a model of GBM and
we refer to them as GBM astrocytes. We obtained high
quality RNA sequencing data as characterized by num-
ber of input reads (3.4 to 4.1 × 106/sample) and the
number of uniquely mapped reads (74–84%). Out of
2567 differentially regulated genes between male and fe-
male GBM astrocytes (Female/Male Nf1−/−;DNp53),
594 were statistically significant at FDR < 0.05 (Fig. 2a).
Consequently, we wanted to investigate whether these
transcriptome-wide sex differences in our murine GBM
model are also present in human GBM. To do so, we
mined the TCGA GBM data sets and found a
Fig. 2 Male and female GBM astrocytes exhibit transcriptome-wide differences. a Heatmap of male and female differentially regulated genes with
2-fold or greater change in expression. b Histogram plot depicting a probability of 10− 6 for a concordance of 50% in gene expression patterns in
mouse and human GBM data sets. c Pathway analysis of differentially regulated genes with concordant expression patterns between mouse and
human GBM was performed using Genomatix GePS
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concordance in expression differences in 49% of these
significantly differentially regulated genes. To determine
whether this concordance in expression between mouse
and human GBM samples could be due to chance, we
randomly selected 100,000 different sets of 500 mouse
genes, and measured the percent of genes that exhibited
concordant sex-specific gene expression. We found that
on average approximately 28% of genes exhibit concord-
ance by chance. We next calculated the probability of
observing a 49% concordance, and found it to be 10− 6.
We therefore concluded that the observed sex differ-
ences in gene expression in our murine GBM model are
representative of sex differences in gene expression that
are present in human GBM (Fig. 2b). Pathway enrich-
ment analysis for the concordant differentially regulated
genes was performed using a combination of KEGG
pathway and Genomatix Pathway System (GePS).
Relevant and important sexually dimorphic pathways
identified, included cell differentiation, cell adhesion,
glioblastoma, proliferation, disorders of sex develop-
ment, and DNA-binding transcription factors (Fig. 2c).
This is the first demonstration of transcriptome-wide
sexual dimorphism in a cancer model and it suggests
that a great breadth of differences between male and fe-
male cells could contribute to differences in their sus-
ceptibility to malignant transformation.
In prior work, we determined that sex differences in in
vivo tumorigenesis of astrocytes rendered null for neuro-
fibromin and p53 function were the result of sexual di-
morphism in Rb function. Upon combined loss of
neurofibromin and p53 function, female cells exhibited a
compensatory protective effect that was evident in
greater inhibition of Rb phosphorylation, lower growth
rates and levels of clonogenic cell function, and less in
vivo tumorigenesis, compared to their male counter-
parts. These sex differences disappeared when Rb and
p53 function were simultaneously abrogated by trans-
formation with SV40 large T antigen [38]. Thus, to begin
an investigation into the mechanisms by which female
cells were protected from transformation upon loss of
neurofibromin and p53 function, we examined the cell
growth rate of astrocytes rendered null for both under
basal and experimental conditions (serum deprivation,
cyclin dependent kinase inhibitors and chemotherapy).
Consistent with our prior findings [37], under 10%
serum containing conditions, male GBM astrocytes pro-
liferate more than their female counterparts (Fig. 3a).
Upon serum deprivation (0.1%), female GBM astrocytes
undergo almost complete growth arrest while male
GBM astrocytes continue to increase in cell number, al-
beit at a greatly diminished rate. Next, we asked whether
we could detect sex differences in cyclin dependent kin-
ase inhibitor (CDKi) cytotoxicity such as PD0332991
(Palbociclib). To measure cytotoxicity, we counted cell
number following Palbociclib treatment using cell Titer-
Glo assay. Palbociclib was more effective in male GBM
astrocytes (Fig. 3b). Finally, to determine the effect of
DNA damage on growth in culture, we treated GBM as-
trocytes with etoposide. Etoposide treatment resulted in
growth arrest in female, but not male GBM astrocytes
(Fig. 3c). Altogether, these data reveal that male and
female GBM cells respond differently to a variety of con-
ditions that would be expected to inhibit Rb phosphoryl-
ation and enhance its function.
To investigate the mechanism underlying these sexu-
ally dimorphic responses, we first examined the expres-
sion of regulators of Rb (p16, p21 and p27) under these
same conditions. When cultured in serum containing
media, there was equivalent expression of p16 mRNA in
both male and female GBM astrocytes (Fig 4a), but little
to no p16 protein expression in either (Fig. 4b). While
abrogation of p53 function results in a dramatic
Fig. 3 Male and female GBM astrocytes display sex differences in response to serum deprivation, CDKi treatment and chemotherapy. a Male and
female GBM astrocytes were grown in either 10% or 0.1% serum and cell number was measured over the course of 96 h by trypan blue exclusion. The
differences in growth rates (n = 3) in 0.1% serum was significant with p < 0.0001 as determined by two-way ANOVA. b Representative dose response
curve for palbociclid treatment of male and female GBM astrocytes. Cell viability was measured with CellTiter Glo. IC50 values were calculated using
four-parameter non-linear regression analysis in Graphpad Prism. c Male and female GBM astrocytes were treated with etoposide (10 μg/ml) or vehicle
for 24 h. At that time, media was changed to 10% FBS supplemented DMEM/F12 and cell number was measured over the course of 4 days by trypan
blue exclusion. The differences in growth rates were significant with p = 0.0001 as determined by two-way ANOVA (n = 3)
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reduction in p21 expression, small levels of p21 expres-
sion remain detectable in both male and female GBM
astrocytes. Under basal serum containing conditions, fe-
male cells exhibited consistently higher levels of p21
protein expression compared to male GBM astrocytes
(Fig. 4b), and equivalent levels of p27 mRNA and pro-
tein expression (Fig. 4a and b). To further evaluate sex
differences in p16, p21 and p27 expression, we performed
Western blot analysis of male (n = 4) and female (n = 4) in
vivo GBM tumor tissue recovered from the CRISPR-IUE
glioma model. While p16 protein was undetectable in
these samples (data not shown), female tumors expressed
significantly greater levels of p21 and trended towards
greater expression of p27 (Additional file 1: Figure S2),
thus, confirming sex differences in these critical negative
regulators of growth. Additionally, concordant gene ex-
pression changes with known interactors of p16, p21 and
p53 were also identified. These include sonic hedgehog
(Shh) and Cyclin D1 (p16 interactors), p63 (p21 interac-
tor), and BTG Anti-Proliferation Factor 2 (Btg2) and High
Mobility Group AT-Hook 2 (Hmga2) (p53 interactors).
Consistent with the in vivo tumorigenesis data, tumor
suppressor genes such as Btg2 and p63 were more highly
expressed in females GBM astrocytes compared to their
male counterparts, while genes involved in tumor progres-
sion and invasion such as Hmga2 and shh were more
highly expressed in male GBM astrocytes compared to
their female counterparts.
p16, p21 and p27 mediate Rb regulation in response to
stressors like changes in growth factor availability and
Fig. 4 Female GBM astrocytes exhibit greater capacity for p16 induction and growth inhibition in response to serum starvation. a p16, p21 and p27
expression was measured by quantitative PCR in male and female GBM astrocytes grown in the presence or absence of 10% serum. Female GBM
astrocytes express higher levels of p16 in response to serum withdrawal (n = 3 independent litters, p < 0.05 as determined by one-way ANOVA and
post-hoc Dunnett’s test). b Expression of p16, p21 and p27 protein was measured by Western blot analysis in the presence or absence of 10% serum
(+). Means and SEM of protein expression was calculated from three independent experiments. Values were normalized within each experiment to
male control. ** = p < 0.005 as determined by one-way ANOVA with Sidaks’ multiple comparisons test. c Flow cytometric analysis of cell cycle
distribution of EDU-labelled male and female GBM astrocytes indicated that male and female cells contain 2 N and 4 N sub-populations and
that under 10% serum containing conditions both are synthesizing DNA. Upon serum deprivation (0.1%), male, but not female, GBM astrocytes
continue to incorporate EDU into both the 2 N and 4 N populations albeit at substantially lower levels than control. d Under basal serum
containing conditions, male GBM astrocytes incorporate significantly greater levels of EDU than their female counterparts (n= 3,* = p= 0.01 as determined
by paired t-test). Upon serum deprivation, male cells incorporate significantly more EDU than female cells (* = p= 0.03 as determined by paired t-test)
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DNA damage [5, 7]. To test whether there were differ-
ences in the responsiveness of these regulators to these
stressors, we examined the expression of p16, p21 and
p27 after serum withdrawal or induction of DNA dam-
age with etoposide. Upon withdrawal of serum for 48 h,
p16 mRNA and protein levels were significantly elevated
in female, but not male GBM astrocytes (Fig. 4a, b).
Serum deprivation resulted in a decline in p21 protein
expression in both male and female GBM astrocytes and
was without effect on p27 expression (Fig. 4a, b). We
further evaluated proliferation in 10% and 0.1% serum
containing conditions with cell cycle analysis and EdU
incorporation. Under 10% serum containing conditions,
both male and female GBM astrocytes are comprised of
2 N and 4 N sub-populations, each of which incorpo-
rated EDU at a high, but significantly different rates
(Male > Female (Fig. 4c, d)). Upon serum deprivation
(0.1%), little EDU incorporation is evident in the female
GBM astrocytes while substantially greater incorporation
of EDU is evident in both the male GBM astrocyte 2 N
and 4 N populations (Fig. 4c, d).
To determine the effect of DNA damage on p16, p21
and p27 expression, we treated GBM astrocytes with eto-
poside. In response to etoposide there was a substantial
increase in p21 mRNA (Fig. 5a) and protein (Fig. 5b) levels
in both male and female GBM astrocytes, but the increase
was greater and more significant in female, compared to
male cells. p27 protein was highly expressed in GBM as-
trocytes and etoposide treatment reduced its expression in
both male and female cells. There was no detectable p16
protein expression under these basal or etoposide treated
conditions (Fig. 5a and b).
To determine whether etoposide treatment was indu-
cing equivalent amounts of DNA damage, we examined
levels of γH2AX, a biomarker of DNA double strand
breaks, by Western blot after etoposide treatment. We
Fig. 5 Female GBM astrocytes exhibit greater capacity for p21 induction and growth inhibition in response to etoposide. a The effect of etoposide
treatment (10 μg/ml for 24 h) on p16, p21 and p27 RNA expression was measured by quantitative PCR. Etoposide induced p21 mRNA expression in
both male and female GBM astrocytes but the level of increase was greater in females compared to male GBM astrocytes. b Expression of p16, p21
and p27 protein was measured by Western blot analysis. Means and SEM of protein expression was calculated from three independent experiments.
Values were normalized within each experiment to male control. ** = p < 0.005 and *** = p < 0.0005 as determined by one-way ANOVA with Sidaks’
multiple comparisons test. c Etoposide treatment resulted in equivalent induction of histone H2AX phosphorylation (γH2AX) in male and female GBM
astrocytes. Shown is a representative Western blot and accompanying quantification of three independent experiments. d Etoposide had greater
clastogenic effects in male compared to female GBM astrocytes. Shown are representative metaphase spreads of etoposide-treated male and female
GBM astrocytes. Male and female GBM astrocytes contained 2 N and 4 N subpopulations. Etoposide induced chromosomal fragmentation in both
sexes but there was a substantially greater clastogenic effect in male compared to female GBM astrocytes
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found that there were equivalent levels of γH2AX, sug-
gesting that the differences in response to etoposide
were not a consequence of differences in the initial levels
of DNA double strand breaks (Fig. 5c). Etoposide is a
well-known clastogen [23] and to determine whether
there were sex differences in etoposide-induced chromo-
somal aberrations, we examined metaphase spreads of
DMSO and etoposide-treated GBM astrocytes.
Karyograms of three metaphase spreads of each of three
male and female GBM astrocytes preparations treated
with etoposide or DMSO were examined in detail for
aneuploidy and structural changes. Consistent with the
aneuploidy observed in the cell cycle analysis, under
DMSO control conditions, both male and female GBM
astrocytes contained subpopulations with chromosome
numbers that varied between 50 and 120, and 41 and
111 respectively (Additional file 1: Figure S3). Little to
no chromosomal structural variants were observed in ei-
ther male or female GBM astrocytes treated with
DMSO. In contrast, etoposide treatment resulted in the
acquisition of chromosomal anomalies in both male and
female GBM astrocytes (Fig. 5d). In males, the numbers
of fragments ranged from 19 to 30 and in females it
ranged between 6 and 15. This difference reached statis-
tical significance (p = 0.02, two-tailed t-test-value for dif-
ference). Taken together, these data suggest that female
GBM astrocytes might be protected from transformation
through the maintenance of more normal cell cycle
regulation in response to growth factor availability and
genotoxic stress. Further, these data suggest that this
might be due to maintenance of p16 and p21 function.
To assess the independent and potentially combinator-
ial roles of p16, p21 and p27 in protecting female cells
from transformation, we abrogated expression of each
alone, and in every combination using CRISPR/Cas9.
The effects of each manipulation on transformation were
evaluated using in vivo tumorigenesis and two under-
lying cellular behaviors previously identified as distin-
guishing male and female functions in this model:
clonogenic cell frequency and regulation of Rb phos-
phorylation. To test in vivo tumorigenesis, we injected 1
million male or female Cas9 control cells or the same
number of female Cas9 cells also expressing sgRNAs to
p16, p21, or p27 alone or in combinations as indicated,
into the flanks of NCR nude mice (n = 15 for p21 KO
and p27 KO, and n = 5 for each of p21-p27 DKO, p16
KO, p21-p16 DKO, p27-p16 DKO and p21-p27-p16
TKO). Loss of target gene expression was determined in
each case by Western blot analysis (Additional file 1:
Figure S4). As we had previously shown and consistent
with the IUE model (see Fig. 1), female Cas9 control
cells were less competent to form tumors than male
Cas9 control cells (Fig. 6a and b). Individual and com-
bined loss of p21 and p27 was without substantial effect
on in vivo tumorigenesis. In contrast, p16 loss alone sig-
nificantly increased female cell tumorigenesis, though
not to male levels. However, combined loss of p16 and
p21, or combined loss of p16-p21-p27 did render female
cells as competent for in vivo tumorigenesis as male
cells. Surprisingly, loss of p27 expression reduced the
tumorigenic effect of p16 loss and was without effect on
the combined p16 and p21 phenotype (Fig. 6b). To-
gether, these data suggested that the relative cell intrinsic
protective effect in female astrocytes was likely to be
mediated by differences in the activities of p16 and p21.
To further explore the cellular behaviors associated
with the differences in in vivo tumorigenesis, we next
measured in vitro clonogenic cell frequency using Ex-
treme Limiting Dilution Assay (ELDA). We found that
p16 alone, but not p21 or p27 alone, significantly in-
creased clonogenic cell frequency to levels comparable
to male GBM astrocytes (Fig. 6c). In contrast to the
tumorigenesis results, p27 enhanced the effects of p21
loss on clonogenic cell frequency to near male levels,
and did not diminish the effect of p16 deletion. Finally,
we examined Rb phosphorylation. As is standard, we
measured the time course and magnitude of Rb phos-
phorylation upon adding serum back after 48 h of star-
vation in all of the cell lines. We found that deletion of
p16 or p21 or p27 alone increased Rb phosphorylation
to levels that were comparable to male Cas9 controls
(Fig. 6d). Combinatorial loss of p16, p21 and p27 had no
additional effect on Rb phosphorylation.
Discussion and conclusions
The motivation for this study was to understand the
mechanisms underlying sex differences in cancer inci-
dence and to explore the implications of these differ-
ences on therapeutic responses. Cancer occurs more
frequently in males than in females overall [34]. With
few exceptions, this is true for all ages, all races, and
most tissues and cell types common to males and fe-
males. It is particularly evident for tumors of the brain
and spinal cord, especially those of neuro-ectodermal
origin [27]. Moreover, more males die from cancer than
females [34]. At the molecular level, there must be dis-
cernible mechanisms by which sexual differentiation in-
teracts with the pathways of tumorigenesis to create the
sex bias in cancer rates. The fact that there are signifi-
cant disparities in the rates and outcomes of cancers be-
tween prepubertal boys and girls [22, 26, 35] indicates
that the biology of sex differences as it relates to cancer
risk cannot be limited to the acute actions of sex hor-
mones, and must also be a consequence of one or both
of two additional effectors of sexual differentiation: 1)
gene dosage differences as a consequence of incomplete
X chromosome inactivation in female cells, and expres-
sion from the non-pseudo-autosomal component of the
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Y chromosome in male cells, and 2) the organizational
or epigenetic actions of in utero and perinatal sex hor-
mones in patterning gene expression and phenotype for
life [4].
In prior studies, we found that sex differences in a
murine model of glioblastoma were the result of sexual
dimorphism in Rb regulation that emerged upon com-
bined loss of neurofibromin and p53 function [37]. In
the current study, our goal was to define the molecular
basis for the differences in Rb regulation and to investi-
gate its relatedness to sex differences in tumorigenesis.
Key new data in this study include the demonstration
that sex differences in the tumorigenic effects of com-
bined neurofibromin and p53 loss are evident across
mouse strains, independent of how neurofibromin and
p53 loss of function is engineered, and insensitive to
whether the loss occurs in vivo or in vitro. The resultant
male and female GBM astrocytes exhibit significant
transcriptome-wide differences in gene expression that
mirror gene expression differences in patient specimens.
A number of important pathways that warrant evalu-
ation in future studies were identified in this cross-
species analysis. In addition, in the absence of p53,
female GBM astrocytes exhibit greater genomic stability
than their male counterparts. Together, these data pro-
vide essential validation of the model for exploring the
molecular mechanisms involved in sex differences in
tumorigenesis. From these data, we conclude that both
p16 and p21 function are essential to protect female
GBM astrocytes from transformation upon combined
loss of neurofibromin and p53 function. While p16 was
the only CDK inhibitor whose loss alone resulted in an
increase in the clonogenic cell fraction of female GBM
astrocytes to levels that were comparable to male Cas9
Fig. 6 Combined loss of p16 and p21 in female GBM astrocytes recapitulates the male GBM phenotype. a Representative flank tumors from male and
female GBM Cas9 control astrocyte initiated tumors. b Quantification of mean and SEM tumor volumes of male and female GBM Cas9 control tumors and
each of the p16, p21 and p27 single and combinatorial KO female cell lines. Tumors were harvested at 8-weeks post-implantation and measurements are
of ex vivo tumors. Statistical significance was determined using either male Cas9 tumors as reference (red asterisks) or female Cas9 tumors as reference
(blue asterisks). Asterisks (1–4) refer to p values of < 0.05, < 0.005, < 0.0005, or < 0.00005 as determined by one-way ANOVA and Dunnett’s post-hoc test
(n= 15 for p21 KO and p27 KO, and n= 5 for each of p21;p27 DKO, p16 KO, p21-p16 DKO, p27-p16 DKO and p21-p27-p16 TKO). c ELDA assays were utilized
to measure clonogenic cell frequency. Asterisks refer to comparisons between male and female Cas9 GBM cells and p-values are as described for panel b.
d The effect of p16, p21 and p27 loss on Rb phosphorylation was measured by Western blot analysis of cells stimulated with serum after 48 h of serum
starvation. Shown are representative blots from individual experiments
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control levels, it was not sufficient alone, to increase in
vivo tumorigenesis to male Cas9 control levels. The
combination of p16 and p21 loss was sufficient to in-
crease in vivo tumorigenesis without any additional in-
crease in clonogenic cell frequency beyond that
observed with p16 deletion. Thus, we concluded that
cooperativity between these factors is necessary to both
protect against aberrant proliferation, and the acquisi-
tion of new DNA mutations. Importantly, the induction
of p16 and p21in female GBM astrocytes occurs in the
absence of p53 function. Though not as potently, mul-
tiple other pathways can induce p21 expression in the
absence of p53 function [1, 16, 17]. In addition, multiple
other regulators of p53 function, such as MDMS and
MDM4, are known to be altered in GBM and could also
contribute to sex differences in p53 function and re-
sponse to treatment.
While loss of p16, p21 or p27 equally abrogated sex
differences in Rb phosphorylation, they did not have
equivalent effects on in vivo tumorigenesis or in vitro
clonogenic cell activity. In particular, p27 deletion sig-
nificantly increased Rb phosphorylation without con-
comitant increases in clonogenic cell function or
tumorigenesis. Combined loss of p16 and p21 was the
only condition sufficient to render female GBM astro-
cytes like their male counterparts across all assays. This
was clear in the in vivo tumorigenesis studies of GBM
astrocytes rendered null for p16, p21 and p27 alone or
in combination. The direct consequence of maintaining
p16 and p21 function is the more normal response to
the loss of growth factor signaling or the induction of
DNA damage. The central importance of sexual di-
morphism in cell cycle regulation and DNA repair was
confirmed by the differences in male and female GBM
astrocyte responses to etoposide treatment in which we
observed sex differences in growth arrest, and substan-
tial differences in the acquisition of chromosomal frag-
ments in dividing cells.
Not only did etoposide treatment result in greater
numbers of chromosomal aberrations, the fact that male
cells did not undergo growth arrest, means that these
aberrant chromosomal fragments are likely to be propa-
gated. In light of new insights into the importance of
extrachromosomal DNA to cancer evolution, this may
be particularly important [42]. Finally, the sex differ-
ences in response to Palbociclib and etoposide strongly
suggest that we must be thinking about incorporating
the potential for sex differences into clinical trial design
and interpretation.
In aggregate, the effect of p16 and p21 loss on the
growth and tumorigenesis assays and transcriptomic ana-
lyses indicate that sex differences in cell cycle regulation
and DNA repair may be central to sex differences in can-
cer incidence. Moreover, these new data speak broadly to
the relatedness between growth regulation and cancer risk
[2, 40]. Growth differences in male and female mamma-
lian embryos are measurable from the moment of
fertilization [3, 6, 8]. By the time of implantation, male hu-
man embryos contain greater numbers of cells than fe-
male embryos [19, 32, 41, 43]. In addition, male embryos
consume more glucose and produce more lactate and
pyruvate [11, 18, 39]. Sex differences in growth rates per-
sist until adulthood resulting in statistically significant
differences in normal adult male and female height. A dif-
ference in adult male and female size is present through-
out primates and can be as large as 4:1.
Ultimately, the importance of studying sex differences in
cancer will be determined by whether it improves out-
comes. While outcome, including the quality of life and
the total numbers of survivors, is likely to be improved by
greater understanding of how sex differences impact on
drug delivery, drug metabolism, toxicity and recovery,
these data indicate that the potential for tumor cell intrin-
sic sex differences in drug sensitivity must also be
accounted for in the plans and execution of clinical trials.
Methods
CRISPR-IUE Glioma model
Primary mouse glioma was generated using in utero
electroporation (IUE) in the CD-1 IGS background as pre-
viously described [21]. Briefly, while under anesthesia, the
uteri of timed pregnant females were exposed at embry-
onic stages E15–16. Two pX330 vectors [13] with guide
sequence inserts targeting NF1 and p53 were injected (at
a concentration of 1.5 μg/μl each) into the lateral ventri-
cles, and progenitor cells were targeted via bioelectropora-
tion (6, 55 msec pulses, at 33 V, set at 100 msec intervals).
Additionally, electroporated cells were also labeled with
the pGlast-PBase and PBCAG-GFP vectors for fluorescent
visualization. Surgical incisions were sutured closed. Mice
recovered and gave birth. Electroporated offspring were
then monitored for abnormal behavioral symptoms
(including but not limited to poor grooming, paralysis,
hunched back, abnormal gate) or for megalencephaly/
hydrocephaly, suggestive of tumor growth. Upon death,
tumors were identified by their GFP fluorescence and
diagnosed as glioblastoma by a neuro-pathologist using
standard histological approaches.
Immunohistochemistry and GFAP staining of mouse
tumor tissues
Tissue samples were dissected and drop fixed in para-
formaldehyde overnight. After embedding the tumor
brains in a paraffin block, brains were sectioned and
mounted. Histological features were analyzed through
hematoxylin and eosin staining or immunohistochem-
istry against GFAP (1:1000; Dako, clone Z0334).
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Immunohistochemical signal was developed with the
ImmPACT DAB Peroxidase Kit (Vector Laboratories,
SK- 4105).
RNA Seq library construction and sequencing
Total RNA was isolated using the RNeasy Mini Kit from
Qiagen (Hilden, Germany) from GBM astrocytes treated
with DMSO (0.05%) or Etoposide at 10 μg/ml for 4 h.
PolyA Selection was performed to create RNA Seq librar-
ies. mRNA was extracted from total RNA using a Dynal
mRNA Direct kit. Sequencing was performed using HiSeq
1 × 50. RNA-seq reads were aligned to the Ensembl re-
lease 76 top-level assembly with STAR version 2.0.4b.
Gene counts were derived from the number of uniquely
aligned unambiguous reads by Subread:featureCount ver-
sion 1.4.5. Transcript counts were produced by Sailfish
version 0.6.3. Sequencing performance was assessed for
total number of aligned reads, total number of uniquely
aligned reads, genes and transcripts detected, ribosomal
fraction known junction saturation and read distribution
over known gene models with RSeQC version 2.3.
All gene-level and transcript counts were then
imported into the R/Bioconductor package EdgeR and
TMM normalization size factors were calculated to ad-
just for samples for differences in library size. Genes or
transcripts not expressed in any sample were excluded
from further analysis. The TMM size factors and the
matrix of counts were then imported into R/Bioconduc-
tor package Limma and weighted likelihoods based on
the observed mean-variance relationship of every gene/
transcript and sample were then calculated for all sam-
ples with the voom With Quality Weights function. Per-
formance of the samples was assessed with a spearman
correlation matrix and multi-dimensional scaling plots.
Gene/transcript performance was assessed with plots of
residual standard deviation of every gene to their average
log-count with a robustly fitted trend line of the resid-
uals. Generalized linear models were then created to test
for gene/transcript level differential expression. Differen-
tially expressed genes and transcripts were then filtered
for FDR adjusted p-values less than or equal to 0.05.
Heat maps and pathway analysis
Heat map analysis was performed using GENE-E software
(Broad Institute). Pathway enrichment analysis for differen-
tially regulated genes was performed using a combination
of KEGG pathway and Genomatix Pathway System (GePS).
GePS uses information extracted from public and propri-
etary databases to display canonical pathways and to create
and extend networks based on literature data. These
sources include NCI-Nature Pathway Interaction Database,
Biocarta, Reactome, Cancer Cell Map, and the ENCODE
Transcription Factor project data. All data for pathway ana-
lysis is presented with adjusted corrected p-values.
TCGA gene expression data analysis
To investigate whether the concordance of expression in
mouse and human GBM samples could be due to ran-
dom chance, we randomly selected 500 differentially
expressed mouse genes and calculated the chance of
having the same expression pattern in human TCGA
samples. We then performed this random selection
100,000 times, fitted the data to normal distribution in R
program and calculated the probability of having 50%
concordance to be less than 10− 6.
Growth assays, serum deprivation, Etoposide treatment
Growth kinetics of male and female GBM astrocytes
with various genetic manipulations were examined by
counting live cell number using an automated T4 cell
counter as previously described with minor modifica-
tions [37]. Briefly, cells were harvested and plated in a 6-
well plate at a density of 2 × 104 cells/well (duplicates/
treatment/genotype/time point/per each independent
experiment) in 10% FBS supplemented DMEM/F12
media. 4-h post plating, cells were harvested by trypsini-
zation and counted in the presence of trypan blue. This
time point was designated as the starting point (T0) of
the time course. Cells were then harvested and counted
every 24 h for a total of 4 days (24, 48, 72 and 96 h). For
serum deprivation experiments, 10% FBS supplemented
media was replaced with DMEM/F12 media containing
no serum or 0.1% FBS as indicated. For etoposide treat-
ment, GBM astrocytes were treated with 10 μg/ml eto-
poside for 24 h, at which time media was changed to
DMEM/F12 with 10% FBS.
Quantitative real-time PCR
Total RNA was isolated using Trizol RNA extraction
method (Invitrogen, CA). cDNA was generated using
the SuperScript III reverse transcriptase (Invitrogen) and
a mixture of poly-dT and random hexamer primers.
Quantitative RT-PCR was performed using gene-specific
primers (Additional file 1: Table S1) and iTaq SYBR
Green PCR master mix (Biorad, CA). Data was analyzed
by standard ΔCq method (2-ΔΔCq) where ΔCq is the dif-
ference between the gene of interest and GAPDH con-
trol Cq value. Similar experimental design was used for
GBM astrocytes grown in the presence of serum or
serum starved for 48 h.
Western blot analysis
Rb phosphorylation kinetics was measured over 24 h of
serum recovery after 48 h of serum starvation as previ-
ously described [37] in male and female Nf1−/-DNp53
cells including Cas9 control and all KO lines. Total cell
lysates (40 μg/lane) from each time point were separated
by electrophoresis on 4–12% gradient Tris-Bis NuPAGE
gels (Invitrogen) and transferred to a nitrocellulose
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membrane for immuno-blotting. After the membrane
was blocked using blocking buffer (Odyssey blocking
buffer 1:1 diluted in 0.1% PBST), primary antibodies di-
luted in the blocking buffer were incubated overnight at
4 °C. Secondary antibodies were diluted in blocking buffer
and added to the membrane for 1 h at room temperature
(in the dark). All blots were scanned by the Odyssey Infra-
Red imaging system (LI-COR) and data were analyzed
using the Odyssey software v3.0. Similar experimental de-
sign was used for GBM astrocytes treated with DMSO
(0.05%) or Etoposide at 10 μg/ml for 24 h. Dilution factors
for both primary and secondary antibodies are included in
the Additional file 1: Table S2.
EDU incorporation flow Cytometry
After incubation with 10 μM EdU, cells were fixed in etha-
nol and resuspended in PBS containing 1% FBS and stored
at 4 °C. 3 × 105 cells were strained through a 70-μm filter,
and the manufacturer's protocol for Click-It EdU Plus Kit
(Invitrogen) was followed. In brief, cells were permeabilized
in PBS containing 0.1% Saponin and 1% BSA. Following
permeabilization, 100 μL of Click-It Plus reaction mix was
added, and the reaction was allowed to proceed for 30 mins.
Cells were washed in PBS with 1% BSA and resuspended in
PBS containing 0.015 mg/mL Propidium Iodide (PI,
Invitrogen) and 0.025 mg/mL RNase A (Invitrogen) for 1 h.
All samples were analyzed on the BD Fortessa using BD
FACSDiva Software. To ensure consistency, a standard was
run with each experiment.
To determine EdU incorporation and DNA ploidy,
data was analyzed using FlowJo. The cell gating para-
digm was consistent across experiments. In brief, cells
were first gated on FSC-A vs SSC-A followed by gating
on FSC-A vs FSC-W to remove doublets. While most
cells were diploid or tetraploid, higher ploidy cells were
inconsistently evident on the PI gate (PE channel) and a
box was drawn to remove these from the analysis.
Chromosome analysis: Karyotyping
Chromosome analysis was performed on male and female
GBM astrocytes treated with DMSO (0.05%) or Etoposide
at 10 μg/ml for 4 h. Cells were allowed to recover for
24–48 h in serum supplemented media following treat-
ment to ensure active division. At that time, cells were
treated in hypotonic solution, fixed and stained for GTG
banding and microscopic evaluation per standard proce-
dures in the Cytogentics Core laboratory of Washington
University School of Medicine. Twenty metaphases for
each cell and condition were counted in order to enumer-
ate the range of chromosomes. Three metaphase spreads
from each cell line and condition were digitally processed
for detailed karyotyping.
Cells, constructs and CRISPR design
Male and female GBM (Nf−/−;DNp53) astrocytes were
generated as previously reported [37] and cells were
grown in DMEM/F12 media supplemented with 10%
FBS and 1% penicillin-streptomycin. CRISPR/Cas9 based
gene depletion was achieved in the GBM astrocytes
using LentiCRISPRv2 (Addgene plasmid: 52,961 by Dr.
Feng Zhang) derived lentiviruses. To express p27-
specific guide RNA, we replaced the Cas9 coding region
in the LentiCRISPRv2 backbone with mCherry as a
flow-sorting marker. We cloned the guide RNA (sgRNA)
targeting the gene of interest into the gRNA expression
system as described [30]. All sgRNAs were designed
using the publicly available CRISPR design tool (http://
www.broadinstitute.org/rnai/public/analysis-tools/sgrna-
design). The top three sgRNAs with the highest scores
and the least off-target potential were selected for fur-
ther functional screening. Guide RNA sequences are
listed in Additional file 1: Table S1.
Knockout (KO) of p21, p27 and p16 in GBM Astrocytes
p21 knockout (p21-KO) lines were generated in the Nf1
−/−;DNp53 astrocytes by infecting them with the lentiviral
Cas9/sgRNA-p21 all-in-one construct. Nf−/−;DNp53-Cas9
control lines were made by viral infection with lentiviral
Cas9 vector without any guide RNA. Both the Cas9 control
and p21-KO lines were selected by puromycin (2.5 μg/ml)
media for 1 to 2 weeks and surviving cells were expanded
for target knockout analysis. To knockout p27, we first
made a p27-specific sgRNA lentiviral vector by replacing
Cas9 gene with an mCherry coding sequence. Then, we
lentivirally expressed the p27-specific sgRNA in the
Nf1−/−;DNp53-Cas9 control lines and mCherry posi-
tive cells were sorted by flow-cytometry (Synergy,
SONY Biotechnology). Similar methodology was used
to prepare the p16 KO lines. To generate the double
and triple knockout lines (p21;p27-DKO, p21;p16-DKO;
p27;p16 -DKO and p21;p27;p16 triple KO), p21-KO
lines were infected with p27 or p16-specific sgRNA
lentiviral vector and selected for mCherry expression.
p21;p27;p16 triple KO lines were generated by infecting
the p21;p27 DKO lines with p16-specific sgRNA lenti-
viral vector and passaging for at least 5 passages for
selection purposes. Gene knockout efficiency was
assessed by Western blot after the knockout lines were
passaged three times, and cells with > 80% knockout of
target protein were used for the functional assays.
In vivo tumorigenesis: Flank implantations
Flank tumors were generated by implanting GBM astro-
cytes with each of the genetic manipulations subcutane-
ously into left and right-side flanks. These cells were
treated with EGF for 1 week (50 ng/ml). One million
cells were then harvested and resuspended in 100 μl of
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1:1 media to matrigel (BD Biosciences) and injected into
the two flanks of mice. In some cases, a third flank
xenograft of male GBM cells was included as a positive
control. Equal numbers of mice received either Cas9
control or KO cells. We have previously shown that
male cells but not female cells grow tumors in vivo, irre-
spective of the sex of the recipient mice, thus only
female mice were used in this study [37].
Clonogenic cell frequency assay: Extreme limiting dilution
assays (ELDA analysis)
Clonogenic capacity of male and female GBM astrocytes
with various genetic manipulations was assayed by the
Extreme Limiting Dilution Assay (ELDA). The frequency
of clonogenic stem cells was evaluated by the cells’ abil-
ity to form tumor-spheres in low-adherent conditions as
previously reported [37]. Briefly, cells were harvested
into a single cell suspension and plated in neurosphere
media containing EGF and FGF on 96-well ultra-low at-
tachment plates in a serial dilution ranging from 3000
cells/well to 1 cell/well (3000, 600, 120, 24, 5 and 1 cells;
n = 14/cell density). Sphere formation was measured
7 days after plating. Clonogenic stem-like cell frequency
was analyzed using the Extreme Limiting Dilution Ana-
lysis software (http://bioinf.wehi.edu.au/software/elda/).
Statistical analysis
All experiments in this study were carried out at least
three times using three independent preparations of
Nf1−/−;DNp53 astrocytes. Two-way ANOVA was used
to evaluate differences in cell growth over time. One-
way ANOVA with a post-hoc Dunnett’s correction
was used to compare the differences in all functional
measurements between p21, p27 and/or p16 knockout
vs. control group. Survival data were evaluated with
log-rank test. In all cases a p-value < 0.05 was consid-
ered statistically significant.
Study approval
Animals were used in accordance with an animal studies
protocol (no. 20150177) approved by the Animal Studies
Committee of the Washington University School of
Medicine per the recommendations of the Guide for the
Care and Use of Laboratory Animals (NIH).
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Figure S2. Sex differences in p21 and p27 expression in the CRISPR-IUE
glioma model. Figure S3. Metaphase spreads from male and female
GBM astrocytes grown under control (DMSO treated) conditions revealed
aneuploidy. Figure S4. Western blot demonstration of p16, p21 and p27
deletion in Cas-9 expressing male and female GBM astrocytes expressing
(+) or not expressing (−) the appropriate guide RNAs (gRNAs) as
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